| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib (NCT05052372) | xCures | 2021-11-21 |
| Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder (NCT04878250) | Queen Mary University of London | 2021-06-01 |
| CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood (NCT04811846) | University Teaching Hospital Hall in Tirol | 2021-03-14 |
| BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer (NCT06462001) | Nottingham University Hospitals NHS Trust | 2020-12-10 |
| Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor (NCT04179110) | Yale University | 2020-09-18 |
| Efficacy and Safety of UGN-101 in Recurrent Patients (NCT04006691) | UroGen Pharma Ltd. | 2019-10-01 |
| Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (NCT03927573) | AvenCell Europe GmbH | 2019-04-15 |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (NCT03896958) | SpeciCare | 2019-03-21 |
| Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors (NCT03238664) | University of Southern California | 2018-01-22 |
| Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (NCT03219775) | AIO-Studien-gGmbH | 2017-07-06 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013) | National Cancer Institute (NCI) | 2017-01-30 |
| Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma (NCT02887248) | SCRI Development Innovations, LLC | 2017-01-12 |
| Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy (NCT03193788) | Asan Medical Center | 2017-01-01 |
| Detecting Transitional Cell Carcinoma From Haematuria (NCT03256877) | Hull University Teaching Hospitals NHS Trust | 2016-10-18 |
| Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma (NCT03296306) | Asan Medical Center | 2016-09-01 |
| Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer (NCT02581982) | Wake Forest University Health Sciences | 2016-04-06 |
| Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT (NCT02471547) | Sheba Medical Center | 2016-01-01 |
| Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery (NCT02420847) | M.D. Anderson Cancer Center | 2015-07-03 |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer (NCT02109328) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2014-08-28 |
| Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (NCT01438112) | CG Oncology, Inc. | 2014-03-01 |
| Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel (NCT01668459) | Dr Anjali Zarkar | 2013-01-01 |
| Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer (NCT01395225) | University of British Columbia | 2011-08-01 |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder (NCT01310803) | Endo USA Inc., a Keenova Therapeutics Company | 2011-05-01 |
| First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma (NCT01215136) | Matthew Galsky | 2010-12-01 |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (NCT01200992) | Bioniche Life Sciences Inc. | 2010-11-01 |
| JAVLOR® Online Non-Interventional Trial (NCT01103544) | Pierre Fabre Pharma GmbH | 2010-04-01 |
| A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy (NCT00714025) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2008-11-01 |
| Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types (NCT00633789) | Bristol-Myers Squibb | 2008-06-01 |
| Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer (NCT00696007) | Lahey Clinic | 2008-04-01 |
| Single Agent Abraxane as Second Line Therapy in Bladder Cancer (NCT00683059) | Sunnybrook Health Sciences Centre | 2008-03-01 |
| A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen (NCT00623831) | Ludwig Institute for Cancer Research | 2007-05-01 |
| First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy (NCT00389155) | Bristol-Myers Squibb | 2007-01-01 |
| Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC (NCT00880334) | Dana-Farber Cancer Institute | 2006-09-01 |
| Relationship of Ochratoxin A to Upper Urologic Cancers (NCT00216801) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2005-09-01 |
| Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium (NCT00101608) | Bristol-Myers Squibb | 2005-01-01 |
| Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging (NCT00612326) | Memorial Sloan Kettering Cancer Center | 2004-06-01 |
| Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas (NCT00070070) | Ludwig Institute for Cancer Research | 2003-10-28 |
| Weekly TP-HDFL in the Treatment of Advanced TCC (NCT00154687) | National Taiwan University Hospital | 2000-10-01 |
| Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC (NCT00173862) | National Taiwan University Hospital | 2000-05-01 |